Srinivas Akkaraju
Director & Co-FounderDr. Srinivas Akkaraju, M.D., Ph.D., also known as Srini, is Director of Psivant Therapeutics, Inc. Dr. Akkaraju is Director at T-Therapeutics Limited. Dr. Akkaraju is Director at Kalaris Therapeutics, Inc. since September 2019 and also its Co-Founder. He is Independent Director of Inventiva S.A. from December 2024. Dr. Akkaraju serves as Board Observer of Autobahn Labs, Inc since 2025 and also served as Board Member until 2025. Dr. Akkaraju is Co-Founder & Executive Chairman of Codex Health, Inc. He is Founder of NALO Therapeutics, Inc. Dr. Akkaraju serves as Independent Director at Alumis Inc. since March 2024. Dr. Akkaraju served as a Board Member at Link Cell Therapies Inc. until January 2026. He is an independent Director at vTv Therapeutics Inc. since February 23, 2024. He serves as Director at OrsoBio, Inc. He is an Independent Director at Scholar Rock Holding Corporation since July 2022. Dr. Akkaraju is Director of Piper Biosciences, Inc. Dr. Akkaraju serves as an Independent Chairman of Jiya Acquisition Corp. Dr. Akkaraju served as Director at A2 Biotherapeutics, Inc until 2025. He is Director at MiroBio Ltd. He served as a Director of Upstream Bio Inc. He serves as Director at Dewpoint Therapeutics, Inc. Dr. Akkaraju serves as Chairman at Tentarix Biotherapeutics. He is the Founder & Managing General Partner at Samsara BioCapital LLC. He founded the firm in 2017. Dr. Akkaraju serves on the Board at Synthekine Inc. and MiroBio Ltd. He served as Chairman of Aravive, Inc. (formerly, Versartis, Inc.) since May 6, 2015 until January 2020. He served as an Independent Director of Aravive, Inc. (previously known as Versartis, Inc.) since July 2013 until April 08, 2020. Dr. Akkaraju was Senior Advisor at Sofinnova Ventures, Inc from April 2013 to March 2017. He was a General Partner at Sofinnova Ventures, Inc. from May 2, 2013 to February 2016. He served as a Managing Director from January 2009 to April 2013 and Lead of West Coast Biopharmaceuticals Practice at New Leaf Venture Partners. Dr. Akkaraju joined New Leaf Venture Partners on January 22, 2009. He co-founded Panorama Capital, LLC and served as its Managing Director from September 2006 to December 2008. Dr. Akkaraju focused primarily on life sciences investments and was part of the Life Sciences Team. He joined J.P. Morgan Partners, LLC in April 2001 and served as a Partner in the life sciences team in the Healthcare Group in 2005, where he was responsible for leading venture investing in biotech companies. From October 1998 to April 2001, he was in the Business and Corporate Development Group at Genentech, Inc. and served as its Senior Manager, where he was responsible for worldwide Partnering activities including technology access deals, in-licensing of early and late-stage therapeutics and out-licensing of Genentech development projects. He also served for the last year as the Project Team Leader for one of Genentech's clinical development products. During this time, Dr. Akkaraju was also a Founding Member at BioStreet. He served as a Director at Principia Biopharma Inc. since February 2011 until June 2019. He served as a Director of Amarin Corporation plc from May 23, 2008 to May 15, 2009 and Pharmos Corp. from October 2006 to March 29, 2011. He served as a Director of Karus Therapeutics Limited and Ophthotech. He had been an Independent Director of aTyr Pharma Inc. from March 31, 2015 until May 15, 2018. He has been an Independent Director at Intercept Pharmaceuticals, Inc. since October 16, 2012. He was Independent Director of Chinook Therapeutics, Inc. since July 2019 until August 11, 2023. He had been an Independent Director of Seattle Genetics, Inc. since July 2003 until August 2020 and served as an Independent Director of Syros Pharmaceuticals, Inc. since June 8, 2017 until 2024. Dr. Akkaraju serves as a Director of Graphite Bio, Alumis, Inventiva, Kalaris and several other private companies. He served as a Director of Barrier Therapeutics Inc. since May 2002, Presidio Pharmaceuticals Inc. since August 29, 2007 and Phenomix Corporation since April 2005. He served as a Director of Synageva BioPharma Corp. from October 20, 2009 to June 27, 2012. He served as an Independent Director of ZS Pharma, Inc. from June 23, 2014 to December 16, 2015. Dr. Akkaraju served as a Director of Piramed Limited, Itero Biopharmaceuticals, LLC, Microscience Limited, Vela Pharmaceuticals, Inc. and BioStreet.com. He served as a Director of Oldtech, Inc. (formerly, Eyetech Pharmaceuticals, Inc.) until July 2001. He is the author of a number of peer-reviewed articles, including ones published in Science and Nature. He concentrated on biopharmaceuticals investments and had experience in life sciences investing and business development. He serves as Director of Eyebiotech Limited. He serves as Independent Director of Mineralys Therapeutics, Inc. since February 2021. Dr. Akkaraju holds a Ph.D. in Immunology and an M.D. in Immunology from the Stanford University of Medicine and a B.S. in Biochemistry and Computer Science from Rice University in 1990.
Positions
- Company NameKalaris Therapeutics, Inc.Stock CodeKLRSPositionDirector & Co-Founder
